Description: Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Home Page: www.helixbiopharma.com
401 Bay Street
Toronto,
ON
M5H 2Y4
Canada
Phone:
905-841-2300
Officers
| Name | Title |
|---|---|
| Mr. Jacek Antas | Chairman & CEO |
| Mr. Praveen Kumar Varshney F.C.A., FCA, FCPA, LLB | CFO & Corporate Secretary |
| Dr. Gabrielle M. Siegers M.A., Ph.D. | Head of R&D |
| Dr. Srikanth Sola | Chief Strategy Officer |
| Dr. Christof Boehler | Chief Business Development Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | |
| Full Time Employees: | 9 |